Alexis AF, Merola JF, Zhong Y, Zhuo J, Becker B, Napoli A, Ross J, Beaumont J, DeRosa M, Banerjee S, Armstrong AW. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. J of Skin [Internet]. 2024Mar.18 [cited 2024Sep.20];8(2):s358. Available from: https://dermsquared.com/skin/article/view/2653